Pathway Intermediates Limited
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Pathway Intermediates Limited (No. 04220119)[1] was founded in 2001 by cancer biologist[2] Dr David Garnett and mathematician Dr Robin Jones. The principal activity of the company is the manufacture of a class of specialty chemicals known as biosurfactants.
The company has its headquarters in Shrewsbury, United Kingdom with additional manufacturing sites in England and South Korea, along with offices in South Korea, USA, China, Thailand and Vietnam.[citation needed]
The company exports to Europe, Asia and the Americas. Significant growth in these markets was recognised in 2012 when the company won a Queen's Awards for Enterprise.[3] In 2011 the company entered a joint venture agreement with Easy Bio Systems[4] of South Korea and established a manufacturing company Pathway Intermediates International Inc,[5] located outside Seoul.[6] In 2018 Easy Bio became the majority shareholder of Pathway Intermediates Limited.
Pathway Intermediates Limited conducts research into novel lysophospholipids, glycosides, glycerides and other esters and this work has attracted research grants from local and national government agencies.[citation needed]
References[edit]
- ^ http://www.companieshouse.gov.uk/ Companies House
- ^ Garnett, D.J. J Cancer Res Clin Oncol (2016) 142: 611. https://doi.org/10.1007/s00432-015-2074-3
- ^ "2012 Winners | the Queen's Awards for Enterprise Magazine". Archived from the original on 15 January 2015. Retrieved 28 March 2015. Queens Award for Enterprise
- ^ "Easy Bio Inc KOREA". Easybio.co.kr. Retrieved 19 February 2019.
- ^ http://www.pathway-international.co.kr/ Pathway Intermediates International Inc
- ^ "Completion-of-LIPIDOL-plant-for-the-World-Markets!" Easy Bio Inc News 20 March 2013